Sign inJoin
Company / Finance

Aardvark Therapeutics, Inc.

AARD · NASDAQ

Official-source baseline for Aardvark Therapeutics using SEC submissions, SEC XBRL companyfacts, FY2025 10-K, Q1 FY2026 10-Q, company-filed results releases, clinical-update 8-Ks, prospectus filings, and peer filings.

FollowAdd to WatchlistAsk Question
NASDAQAARDCoverage BootstrapBiotechnologyMetabolic DiseasePrader-Willi Syndrome
Latest ReportMay 13, 2026Aardvark Therapeutics (AARD) Coverage Bootstrap: a paused clinical-stage obesity and PWS biotechView report ->Total Reports1Published reportView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->
Company filters1 company reports
Latest Thesis

Aardvark Therapeutics (AARD) Coverage Bootstrap: a paused clinical-stage obesity and PWS biotech

Official-source baseline for Aardvark Therapeutics using SEC submissions, SEC XBRL companyfacts, FY2025 10-K, Q1 FY2026 10-Q, company-filed results releases, clinical-update 8-Ks, prospectus filings, and peer filings.

May 13, 2026Research reportSlides available
Read reportOpen slidesDiscussion (0)
Aardvark Therapeutics, Inc.Therapeutics (AARD) Coverage Bootstrap: a paused clinical-stage May 13, 2026
Member workspace

Financials and workspace tools are for paid members.

Paid login unlocks company financials, filing timeline, peer comparison, scorecard, and discussion. Valuation remains admin-only while we finalize market-data licensing.

Sign in to continue

Recent Reports

Compact report index for this company.

View all 1 reports ->
ReportTypeUpdatedReadActions
Aardvark Therapeutics (AARD) Coverage Bootstrap: a paused clinical-stage obesity and PWS biotechOfficial-source baseline for Aardvark Therapeutics using SEC submissions, SEC XBRL companyfacts, FY2025 10-K, Q1 FY2026 10-Q, company-filed results releases, clinical-update 8-Ks, prospectus filings, and peer filings.NASDAQMay 13, 2026Research reportReadSlides